Repertoires of SARS-CoV-2 epitopes targeted by antibodies vary according to severity of COVID-19

References

• Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27(7):1205–1211.
   PubMed Web of Science ®Google Scholar
• Hall VJ, Foulkes S, Charlett A, et al. SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN). Lancet. 2021;397(10283):1459–1469. DOI:10.1016/S0140-6736(21)00675-9
   PubMed Web of Science ®Google Scholar
• Verma A, Hawes CE, Lakshmanappa YS, et al. Monoclonal antibodies protect aged rhesus macaques from SARS-CoV-2-induced immune activation and neuroinflammation. Cell Rep. 2021;37(5):109942. DOI:10.1016/j.celrep.2021.109942
   PubMed Web of Science ®Google Scholar
• Israelow B, Mao T, Klein J, et al. Adaptive immune determinants of viral clearance and protection in mouse models of SARS-CoV-2. Sci Immunol. 2021;6(64):eabl4509.
   PubMed Web of Science ®Google Scholar
• Wheatley AK, Pymm P, Esterbauer R, et al. Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain. Cell Rep. 2021;37(2):109822. DOI:10.1016/j.celrep.2021.109822.
   PubMed Web of Science ®Google Scholar
• Kreuzberger N, Hirsch C, Chai KL, et al. SARS-CoV-2-Neutralising monoclonal antibodies for treatment of COVID-19. Cochrane Database Syst Rev. 2021;9(9):CD013825. DOI:10.1002/14651858.CD013825.pub2
   PubMedGoogle Scholar
• Garcia-Beltran WF, Lam EC, Astudillo MG, et al. COVID-19-Neutralizing antibodies predict disease severity and survival. Cell. 2021;184(2):476–488.e11. DOI:10.1016/j.cell.2020.12.015
   PubMed Web of Science ®Google Scholar
• Atyeo C, Fischinger S, Zohar T, et al. Distinct early serological signatures track with SARS-CoV-2 survival. Immunity. 2020;53(3):524–532.e4. DOI:10.1016/j.immuni.2020.07.020
   PubMed Web of Science ®Google Scholar
• Ren L, Zhang L, Chang D, et al. The kinetics of humoral response and its relationship with the disease severity in COVID-19. Commun Biol. 2020;3(1):780. DOI:10.1038/s42003-020-01526-8
   PubMed Web of Science ®Google Scholar
• Guthmiller JJ, Stovicek O, Wang J, et al. SARS-CoV-2 infection severity is linked to superior humoral immunity against the spike. Mbio. 2021;12(1):e02940–20. DOI:10.1128/mBio.02940-20
   PubMed Web of Science ®Google Scholar
• de Candia P, Prattichizzo F, Garavelli S, et al. Effect of time and titer in convalescent plasma therapy for COVID-19. Iscience. 2021;24(8):102898.
   PubMed Web of Science ®Google Scholar
• Chakraborty S, Gonzalez J, Edwards K, et al. Proinflammatory IgG Fc structures in patients with severe COVID-19. Nat Immunol. 2021;22(1):67–73. DOI:10.1038/s41590-020-00828-7
   PubMed Web of Science ®Google Scholar
• Larsen MD, de Graaf EL, Sonneveld ME, et al. Afucosylated IgG characterizes enveloped viral responses and correlates with COVID-19 severity. Science. 2021;371(6532):eabc8378. DOI:10.1126/science.abc8378
   PubMed Web of Science ®Google Scholar
• Yates JL, Ehrbar DJ, Hunt DT, et al. Serological analysis reveals an imbalanced IgG subclass composition associated with COVID-19 disease severity. Cell Reports Med. 2021;2(7):100329. DOI:10.1016/j.xcrm.2021.100329
   PubMedGoogle Scholar
• Shrock E, Fujimura E, Kula T, et al. Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity. Science. 2020;370(6520):eabd4250. DOI:10.1126/science.abd4250
   PubMed Web of Science ®Google Scholar
• Amrun SN, Lee C-P, Lee B, et al. Linear B-cell epitopes in the spike and nucleocapsid proteins as markers of SARS-CoV-2 exposure and disease severity. EBioMedicine. 2020;58:102911.
   PubMed Web of Science ®Google Scholar
• Heffron AS, McIlwain SJ, Amjadi MF, et al. The landscape of antibody binding in SARS-CoV-2 infection. PLoS Biol. 2021;19(6):e3001265. DOI:10.1371/journal.pbio.3001265.
   PubMed Web of Science ®Google Scholar
• Voss C, Esmail S, Liu X, et al. Epitope-Specific antibody responses differentiate COVID-19 outcomes and variants of concern. JCI Insight. 2021;6(13). DOI:10.1172/jci.insight.148855
   PubMed Web of Science ®Google Scholar
• Lu S, Xie X, Zhao L, et al. The immunodominant and neutralization linear epitopes for SARS-CoV-2. Cell Rep. 2021;34(4):108666. DOI:10.1016/j.celrep.2020.108666
   PubMed Web of Science ®Google Scholar
• Ravichandran S, Lee Y, Grubbs G, et al. Longitudinal antibody repertoire in “mild” versus “severe” COVID-19 patients reveals immune markers associated with disease severity and resolution. Sci Adv. 2021;7(10). DOI:10.1126/sciadv.abf2467
   Web of Science ®Google Scholar
• Poh CM, Carissimo G, Wang B, et al. Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients. Nat Commun. 2020;11(1):2806. DOI:10.1038/s41467-020-16638-2
   PubMed Web of Science ®Google Scholar
• Gorse GJ, Patel GB, Vitale JN, et al. Prevalence of antibodies to four human coronaviruses is lower in Nasal Secretions than in Serum. Clin Vaccine Immunol. 2010;17(12):1875–1880.
   PubMedGoogle Scholar
• Dugas M, Grote-Westrick T, Vollenberg R, et al. Less severe course of COVID-19 is associated with elevated levels of antibodies against seasonal human coronaviruses OC43 and HKU1 (HCoV OC43, HCoV HKU1). Int J Infect Dis. 2021;105:304–306.
   PubMed Web of Science ®Google Scholar
• Gouma S, Weirick ME, Bolton MJ, et al. Health care worker seromonitoring reveals complex relationships between common coronavirus antibodies and COVID-19 symptom duration. JCI Insight. 2021;6(16). DOI:10.1172/jci.insight.150449
   PubMed Web of Science ®Google Scholar
• Edridge AWD, Kaczorowska J, Hoste ACR, et al. Seasonal coronavirus protective immunity is short-lasting. Nat Med. 2020;26(11):1691–1693. DOI:10.1038/s41591-020-1083-1
   PubMed Web of Science ®Google Scholar
• Naranbhai V, Chang CC, Beltran WFG, et al. High seroprevalence of anti-SARS-CoV-2 antibodies in Chelsea, Massachusetts. J Infect Dis. 2020;222(12):1955–1959. DOI:10.1093/infdis/jiaa579
   PubMed Web of Science ®Google Scholar
• Romano SD, Blackstock AJ, Taylor EV, et al. Trends in racial and ethnic disparities in COVID-19 hospitalizations, by region — United States, March–December 2020. MMWR Morb Mortal Wkly Rep. 2021;70(15):560–565.
   PubMed Web of Science ®Google Scholar
• Zhou W, Wang W, Wang H, et al. First infection by all four non-severe acute respiratory syndrome human coronaviruses takes place during childhood. BMC Infect Dis. 2013;13(1):433.
   PubMedGoogle Scholar
• Woudenberg T, Pelleau S, Anna F, et al. Humoral immunity to SARS-CoV-2 and seasonal coronaviruses in children and adults in north-eastern France. EBioMedicine. 2021;70:103495.
   PubMed Web of Science ®Google Scholar
• Jiang S, Hillyer C, Du L. Neutralizing antibodies against SARS-CoV-2 and other human coronaviruses. Trends Immunol. 2020;41(5):355–359.
   PubMed Web of Science ®Google Scholar
• Cueno ME, Imai K. Structural comparison of the SARS CoV 2 spike protein relative to other human-infecting coronaviruses. Front Med. 2021;7. DOI:10.3389/fmed.2020.594439
   Web of Science ®Google Scholar
• Chen Z, Boon SS, Wang MH, et al. Genomic and evolutionary comparison between SARS-CoV-2 and other human coronaviruses. J Virol Methods. 2021;289:114032.
   PubMed Web of Science ®Google Scholar
• Okba NMA, Muller MA, Li W, et al. SARS-CoV-2 specific antibody responses in COVID-19 patients. medRxiv. 2020: 2020.03.18.20038059.
   Google Scholar
• Sun Z, Zheng X, Ji F, et al. Mass spectrometry analysis of SARS-CoV-2 nucleocapsid protein reveals camouflaging glycans and unique post-translational modifications. Infect Microbes Dis. 2021;3:149–157.
   Google Scholar
• Chen X, Pan Z, Yue S, et al. Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19. Signal Transduct Target Ther. 2020;5(1):180. DOI:10.1038/s41392-020-00301-9
   PubMed Web of Science ®Google Scholar
• Hansen CB, Jarlhelt I, Pérez-Alós L, et al. SARS-CoV-2 antibody responses are correlated to disease severity in COVID-19 convalescent individuals. J Immunol. 2021;206(1):109 LP–117. DOI:10.4049/jimmunol.2000898
   Web of Science ®Google Scholar
• Long Q-X, Tang X-J, Shi Q-L, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med. 2020;26(8):1200–1204. DOI:10.1038/s41591-020-0965-6
   PubMed Web of Science ®Google Scholar
• Morgenlander WR, Henson SN, Monaco DR, et al. Antibody responses to endemic coronaviruses modulate COVID-19 convalescent plasma functionality. J Clin Invest. 2021;131(7):131. DOI:10.1172/JCI146927
   Web of Science ®Google Scholar
• Garcia-Beltran WF, St Denis KJ, Hoelzemer A, et al. mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. medRxiv. 2021: 2021.12.14.21267755.
   Google Scholar
• Garcia-Beltran WF, Lam EC, St Denis K, et al. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell. 2021;184(9):2372–2383.e9. DOI:10.1016/j.cell.2021.03.013
   PubMed Web of Science ®Google Scholar
• Kaplonek P, Wang C, Bartsch Y, et al. Early cross-coronavirus reactive signatures of humoral immunity against COVID-19. Sci Immunol. 2021;6(64):eabj2901. DOI:10.1126/sciimmunol.abj2901
   PubMed Web of Science ®Google Scholar
• Secchi M, Bazzigaluppi E, Brigatti C, et al. COVID-19 survival associates with the immunoglobulin response to the SARS-CoV-2 spike receptor binding domain. J Clin Invest. 2020;130(12):6366–6378. DOI:10.1172/JCI142804
   PubMed Web of Science ®Google Scholar
• Iyer AS, Jones FK, Nodoushani A, et al. Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients. Sci Immunol. 2020;5(52). DOI:10.1126/sciimmunol.abe0367
   PubMed Web of Science ®Google Scholar